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Clinical Commentary ReviewWhat We Mean When We Talk About Adherence in
Respiratory MedicineBernard Vrijens, PhDa,b, Alexandra L. Dima, PhDc, Eric Van Ganse, MD, PhD, FRCPd,e, Job F.M. van Boven, PharmD, PhDf,
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Baltimore, Md; Sydney, Australia; and Aberdeen and Cambridge, UKAdequate medication adherence is key for optimal beneﬁt of
pharmacological treatments. A wealth of research has been
conducted to understand and identify opportunities to
intervene to improve medication adherence, but variations in
adherence deﬁnitions within prior research have led to
ambiguity in study ﬁndings. The lack of a standard taxonomy
hinders the development of cumulative science in adherence
research. This article reviews the newly established Ascertaining
Barriers to Compliance (ABC) taxonomy for medication
adherence with a particular focus on its relevance and
applicability within the context of asthma and chronic
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Respiratory clinicians have access to a wide range of efﬁca-
cious therapies. Randomized controlled trials (RCTs) have
repeatedly demonstrated the efﬁcacy of licensed asthma and
chronic obstructive pulmonary disease (COPD) therapies in
terms of their ability to minimize symptom burden, improve
health-related quality of life, and maintain or slow disease
progression.1,2 Yet reports of numerous asthma and COPD
exacerbations and related pressures on emergency and respira-
tory services persist.3,4 This apparent disconnect is primarily
explained by the gap between efﬁcacy results derived from
well-controlled, short-term RCTs involving highly selected
populations and effectiveness evaluations conducted in more
every day, real-life settings, typically involving diverse patient
populations, across a wide range of care settings and patient
characteristics and evaluated over longer time intervals than are
used in RCTs.5
One of the important differentiating factors between efﬁcacy
RCTs and real-world effectiveness studies is medication adher-
ence optimized in RCTs, but commonly suboptimal in everyday
routine care. Through registration RCTs, regulatory authorities
require an estimate of efﬁcacy (or “method-effectiveness”) that
assumes perfect adherence while, in practice, payers are often
more interested in “use effectiveness” to inform cost-effectiveness
analyses and guide market access and reimbursement decisions
through pragmatic RCTs or noninterventional studies. All study
designs reﬂect some aspect of the real world, but the ability to
extrapolate the ﬁndings of registration RCTs to more routine
clinical environments must be treated with caution.6 The real-
world implications of differences between registration RCTs
and routine care adherence behaviors depend on the character-
istics of both the disease and the medications as drug actions are
inherently dose and time dependent. As a result, variable under-
dosing (which is the norm) diminishes the actions of medications
in real life by various degrees compared with RCT settings.7The importance of optimizing asthma medication in the
context of routine (“real-world”) practice was recognized and
stressed by the World Allergy Organization and Interasma in
their joint manifesto on adherence to asthma treatment in res-
piratory allergy (also endorsed by Allergic Rhinitis and Its Impact
on Asthma and the Global Allergy and Asthma European
Network).8
The Ascertaining Barriers to Compliance (ABC) taxonomy
began as an initiative of the European Union to standardize
adherence-related terminology for clinical and research use.9 The
publication of the ABC taxonomy marked an important step
forward in the standardization and future development of
adherence research. To facilitate its use in respiratory research
and practice, it is now important to consider its applicability and
relevance to the real-life complexities of respiratory care.
Although sharing many of the common barriers to optimal
adherence reported in other chronic diseases,10,11 asthma and
COPD stand apart because of the central role that inhaled
therapy plays in their management, and the associated challenges
that the effective inhaler technique presents to optimum therapy
delivery and adherence.12 Furthermore, the 2 conditions differ in
their age of onset, pattern of symptoms, and disease course giving
rise to potential differences in respective medication adherence
behaviors. We consider the value of the ABC taxonomy in
differentiating between adherence behaviors and clinical settings
in these respiratory conditions, as a way to both understand
behavior-speciﬁc determinants and establish a new standard for
future respiratory adherence research. Finally, evidence gaps and
unmet needs are outlined to act as a guide for future respiratory
adherence researchers.TOWARDS A COMMON ADHERENCE TAXONOMY
On the basis of a systematic review of the medication adher-
ence literature, Vrijens et al’s9 proposed ABC taxonomy con-
ceptualizes adherence to medications in line with principles of
behavioral and pharmacological science. This proposal was
developed as a response to a 2003 World Health Organization
call for action to address the disease burden associated with poor
medication adherence.13 It also furthered the thinking laid
out by the International Society for Pharmacoeconomics and
Outcomes Research in their 2008 consensus statement on
adherence deﬁnitions.14,15
The ABC taxonomy deﬁnes the overarching concept of
“medication adherence” as the process by which patients take
their medication as prescribed and subdivides it into 3 essential
elements: (A) initiation; (B) implementation, and (C) persistence
(see Figure 1). This subdivision outlines the sequence of events
that have to occur for a patient to experience the optimal beneﬁt
from his or her prescribed treatment regimen.
Step “A” in the process, “initiation”—when the patient
takes the ﬁrst dose of a prescribed medication—is typically a
binary event (patients either start taking their medication or
not in a given time period). In contrast, step “B,” “imple-
mentation”—the extent to which a patient’s actual dosing
corresponds to the prescribed dosing regimen, from initiation
until the last dose is taken—is a longitudinal description of
patient behavior over time, that is, his or her dosing history.
The ﬁnal step “C,” deﬁned within the taxonomy, “persis-





First dose Last dose End of Prescribing
TIME 
Legend: Taken dose Missed dose
FIGURE 1. Illustration of the temporal phases of adherence outlined in the ABC taxonomy.9 Adapted from Vrijens et al.9
J ALLERGY CLIN IMMUNOL PRACT
SEPTEMBER/OCTOBER 2016
804 VRIJENS ETALtreatment discontinuation (ie, time to event); after discontin-
uation, a period of nonpersistence may follow until the end of
the prescribing period.
A further adherence concept, although not speciﬁcally deﬁned
in the ABC taxonomy, is that of medication “reinitiation.” The
temporal steps of initiation, implementation, and persistence
deﬁned by the taxonomy, in research terms, occur (or not) in a
time period in which a speciﬁc medication is prescribed for
regular intake to improve health outcomes, starting with a ﬁrst
prescription and ending after a drug exposure period deemed
sufﬁcient for achieving the expected effect. In RCTs, this
sequence maps onto the process of study participation, from
study inclusion to assessment of health outcomes. Thus, initia-
tion is by deﬁnition a single event, and nonpersistence is readily
operationalized as the time interval between the last medication
intake to the end of the follow-up period (and consequently
depends on the length of this period).
In observational studies and clinical practice, the boundaries
of this temporal sequence are less clear-cut and require additional
speciﬁcations. For chronic conditions, patients can receive
multiple prescriptions often over decades. Over this time inter-
val, they may interrupt or change treatment (in consultation
with the clinician or not) and they may alternate periods of
substantial drug exposure with intervals without any drug
exposure. Epidemiological research has employed the concepts of
“treatment episodes” and “treatment gaps” to reﬂect such clinical
realities, using time intervals for medication exposure represen-
tative of such behaviors derived from long-term patient
records.16 The 3 elements of the ABC taxonomy can be applied
in long-term research and patient care in combination with these
concepts. As such, a patient may have several treatment episodes,
which may show different (re)initiation, implementation,
and discontinuation values. Depending on the available data
sources, the researcher or clinician may have the opportunity to
assess more or less precisely these 3 elements.APPLYING AND INTERPRETING THE ABC
TAXONOMY IN THE CONTEXT OF ROUTINE
ASTHMA AND COPD CARE
Asthma and COPD: clinical management similarities
and differences
To explore the applicability of the ABC taxonomy in the
context of asthma and COPD, it is important to consider the
main characteristics of 2 conditions and their management.
Asthma and COPD are both chronic obstructive lung con-
ditions principally managed with inhaled therapies. There are 2
main categories of inhaled therapies prescribed in asthma and
COPD: bronchodilators (short- or long-acting) to offer symptom
relief, and anti-inﬂammatory therapy to target airway inﬂam-
mation and minimize risk of future exacerbations (ie, acute
periods of worsening).2,3 Beyond these similarities in clinical
presentation and therapeutic management, there are important
differences between the 2 conditions that must be taken into
consideration when evaluating adherence.
COPD considerations. COPD is characterized by ﬁxed
airﬂow obstruction, progressive, irreversible deterioration in lung
function, older age of onset, and mediated primarily by
neutrophilic inﬂammation.2 Short- and long-acting bronchodi-
lators, in the form of anti-muscarinics and b2-agonists, are the
core pillar of COPD management. Inhaled corticosteroids are
often prescribed, although only licensed for use in combination
with bronchodilator therapy. Other treatment options exist, such
as theophylline and phosphodiesterase-4 inhibitors. As a result of
the ﬁxed airﬂow obstruction and progressive lung function
decline over time, COPD symptoms tend to be persistent and
to occur in older patients (>50 years), resulting in a need for
consideration of potential comorbidities and polypharmacy
factors, cognitive implications, and tailoring of inhaler device
(eg, potentially avoiding those requiring strong inspiratory ﬂow).
Costello et al discuss age-related determinants of respiratory
FIGURE 2. Failure to initiate: primary nonadherence to newly prescribed medication (patients aged 19 y).16 Reproduced from Fischer
et al19 with permission from the publisher.
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Asthma considerations. In contrast, asthma is a variable
condition (often triggered by seasonal, viral, and/or environ-
mental exposures) with reversible airﬂow obstruction.1 It is pri-
marily mediated by eosinophilic inﬂammation and can affect
patients of any age (sometimes resolving over time), presenting
different management challenges (eg, in terms of inhalation
technique and successful delivery) depending on the particular
age group under consideration. Inhaled corticosteroids are
the mainstay of anti-inﬂammatory controller therapy and are
prescribed in combination with short- and/or long-acting bron-
chodilators (b2-agonists) for symptom relief. Add-on therapies,
such as oral steroids and/or monoclonal antibodies, are used in
more severe cases. The Global Initiative for Asthma guidelines
recommend a stepwise approach to management, with symptoms
and risk optimized on the lowest dose of therapy appropriate, but
stepped up, as required, to improve control. Use of add-on
therapies (eg, theophylline and/or high-cost biologics) is rec-
ommended only in patients with severe asthma who have
persistent symptoms and/or exacerbations despite optimized
treatment with high-dose controller medications and treatment
of modiﬁable risk factors. Thus, valid means of measuring
and monitoring adherence are required to guide necessary ther-
apy step-ups and, similarly, to avoid unnecessary treatment
escalations.
Yet owing to the sometimes variable nature of asthma,
clinician-issued prescribing instructions can vary substantially
between patients. For instance, daily controller medication use
may be prescribed during a speciﬁc interval each year to treat
seasonal asthma. In contrast, patients with persistent asthma maybe prescribed daily controllers for long-term use, either with a
ﬁxed daily dosage or via a self-management plan, which typically
speciﬁes a ﬁxed basis of daily controller use, rules for reliever use
(eg, “as needed”), and thresholds for increased controller use.
Prescribing instructions are an important element of mean-
ingful adherence appraisal as its evaluation requires a comparison
of actual medication use against a clinically appropriate intended
reference regimen. Furthermore, waxing and waning symptoms
can lead to practical research challenges of differentiating
between periods of episodic implementation and nonpersistence
and temporary nonpersistence (and reinitiation). Therefore,
disease severity, prescription recommendations, and time
intervals need to be carefully considered in asthma adherence
research.
Medication initiation
Initiation in observational studies versus RCTs. Most
treatment initiation research comes from observational studies
using electronic medical records (EMRs) combined with phar-
macy dispensing databases. Unlike RCTs, which typically
administer the ﬁrst dose on site, EMR-based studies draw on
data captured within routine practice and can better reﬂect true
initiation behaviors. However, evidence is scarce as treatment
initiation is not often reported.
Indeed, a systematic review of observational evidence on
medication adherence determinants in asthma, which used the
ABC taxonomy to identify which of the 3 stages were investi-
gated in the studies included, found the vast majority focused on
implementation; very few considered initiation or persistence.18
Yet medication initiation should never be assumed. A
community-based study of initiation rates of chronic disease
medications in the United States found that 20% to 30% of
TABLE I. Some key features, strengths, and limitations of commonly used adherence measurement methods
1. Initiation 2. Implementation 3. Discontinuation
Routine EHR*
Granularity/Precision† Granularity in days, if the
prescription database is also
available
Imprecise—tends to average usage of
a time interval of 3 months
Granularity in weeks or months
Validityz Relatively high (if ﬁrst use follows
dispensation)
Relatively high (if standard dosing
regimen or if prescription details
are available)
Relatively high (if all sources of
dispensation are known)
Allows identiﬁcation of changes in a
same class of medications
Ease of Access Few linked datasets to compare
prescribed and collected
medication dates
Easy to access if available in health
system
Easy to access if available in health
system
Patient reports
Granularity/Precision† Granularity in days/weeks (depends
on the time window of the tool
used)
Imprecise due to recall bias Granularity in days/weeks (depends
on patient memory)
Validityz Subject to desirability bias Subject to desirability bias Subject to desirability bias
Ease of Use Easy to implement. May require an
additional contact with the
patient after prescription
Easy to implement at point of care
Adds burden to the patient
Easy to implement at point of care
Electronic monitoring
Granularity/Precision† Granularity in minutes Granularity in minutes Granularity in minutes
Validityz High (if ﬁrst device use is followed
by inhalation)
High (especially if inhaler technique
is also assessed)
High (if medication is only used with
the device)
Ease of Use Easy to implement in clinical trials
In medical practice, can be used as a
good start program but requires
activation and patient
engagement
Easy to implement in clinical trials
In medical practice, can be used at
speciﬁc time of care (when a
problem is suspected, at
treatment failure, or to support a
behavioral intervention, etc.) for
a deﬁned period of time
Easy to implement in clinical trials
Not feasible for long-term treatments
in large-scale populations—
limited use due to complexity,
costs, patient burden, limited
availability, and fatigue
EHR, Electronic health records.
*Electronic Health Records, e.g. prescription (prescribing and/or dispensing) data, and health insurance (or ‘claims’) data.
†Granularity: the sampling rate at which it is possible to assess changes in the dynamic process of adherence (particularly relevant to objective measures); Precision: degree of
reproducibility, that is, ability to measure the same value repeatedly (particularly relevant to patient reports).
zDegree of potential systematic error in the measurement, that is, difference between the estimated and real value.
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Although asthma medications were among the higher
dispensed e-prescriptions within the study, approximately one-
quarter of patients prescribed new asthma therapy failed to
collect their ﬁrst prescription (see Figure 2).
Measurement of initiation. Pharmacy dispensing databases
provide the best source for evaluating treatment initiation be-
haviors in observational studies, especially when linked to clinical
EMRs (eg, primary and/or secondary care prescribing data; see
Table I). EMR data indicate the physician’s intention that a
patient should take a speciﬁc drug and pharmacy dispensing data
indicate the patient’s collection of the prescribed therapy—one
step closer to the act of initiation. A prescription event followed
by a dispensation event for the same treatment is used in research
to infer therapy initiation.
Patient reports, that is, directly asking patients whether they
started their prescribed treatment, provide a subjective means of
assessing medication initiation. If answered truthfully, they are a
direct method of assessing initiation and for capturing potential
insights into the reasons and determinants of noninitiation. As
with all patient reports, initiation reports will be limited by the
reliability of patient responses and informed by the speciﬁcityand appropriateness of the questions asked; careful design of
assessment timing and tools can optimize the accuracy of the
reports.
Electronic monitors provide an objective means by which the
date of ﬁrst treatment administration can be captured. Electronic
monitors are the gold standard for precisely recording ﬁrst
treatment administration in clinical trials. In medical practice,
after a prescription, the patient has to acquire the medication ﬁrst
and only then the electronic monitor can be activated, limiting
its ability to fully capture treatment initiation in real life.Determinants of initiation. In routine care, treatment
initiation can be affected by a range of demographic, psycho-
logical, and practical factors, among them: denial or uncertainty
of diagnosis20; lack of trust in health care professionals; medi-
cation fears; health literacy; affordability and access to therapy,
age, ethnicity and sex.21,22 In one study designed to evaluate
determinants of initiation of asthma controller medication, for
example, a higher probability of noninitiation was recorded in
younger patients, female patients, those of African American
ethnicity (vs white), and in those who had with fewer short-
acting b2-agonist reﬁlls in the preceding year.
22
FIGURE 3. Aggregate EMR measures of implementation can result in a loss of the detail necessary to interpret and differentiate between
clinically distinct implementation behaviors and between suboptimal implementation and persistence.9 Examples of electronically
compiled drug dosing history based on EMD in 3 patients for whom a twice-daily dosing regimen was prescribed. Dots indicate the dates
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inhaled mode of therapy delivery can present an additional
obstacle, particularly in certain age and cultural groups owing to
substantial stigma around the use of medication inhalers.
Research is needed to determine the extent to which stigma
may prevent initiation and (if collected and administered once)
subsequent implementation and persistence.22,23
Implications for research and practice. The limited
evidence available on treatment initiation suggests that a sub-
stantial proportion of patients with chronic disease fail to
implement chronic disease therapies and highlights the need for a
greater focus on treatment initiation research in asthma and
COPD.
Medication Implementation
Implementation in observational studies versus
RCTs. Interest in implementation originally stems from RCTs,
where accurate estimates of drug exposure are essential for
the evaluation of drug efﬁcacy and safety. However, the highly
selective inclusion criteria applied to clinical trial populations,
coupled with the close monitoring, short duration, and support of
correct implementation, end up reducing variation and the
representativeness of RCT data with respect to real-life settings. In
contrast, cohort studies that observe rather than affect clinical
practice tend to include broader, more representative patient
populations and explore a wider range of determinants and effects.
Measurement of implementation. As the more
commonly studied concept within the adherence sequence,22
several measures of implementation are available for research
and clinical practice (see Table I). Electronic monitoring is the
gold standard approach to measuring the implementation of a
dosing regimen reliably and precisely (permitting granular data
capture). For inhaled therapies, given the difﬁculty associated
with the inhalation technique, electronic monitoring devices
(EMDs) that have the capacity not only to record (and time/
date-stamp) administration (see Figure 3), but also to capture
the quality of therapy delivery (eg, inhalation technique) are
preferred.24,25 EMDs should be systematically used in RCTs as
they provide an accurate means of evaluating drug usage and
exposure.26-28
Dispensing data provide information for various algorithms
estimating medication implementation, known as CMA
(continuous multiple-interval measures of medication availabil-
ity), MPR (medication possession ratio), or proportion of days
covered. Yet although dispensing event data are often the only
data source available in large-scale assessments of implementa-
tion, they lack granularity and can only generate implementation
estimates over longer time intervals based on the ratio of days of
medication dispensed in a given period of evaluation versus the
number of days in that time period. When detailed, time-
stamped EMD data can be acquired, it becomes obvious that
aggregating data in CMA-like scores lead to loss of informationand times of drug intake. Bars indicate missed doses. A, Patient with l
implementation (missed single and consecutive doses, large variability
but short persistence (early discontinuation). EMD, Electronic moni
permission from Vrijens B, De Geest S, Huges DA, Przemyslaw K, De
defining adherence to medications. Br J Clin Pharmacol 2012;73:691on distinct adherence behaviors. Figure 3 illustrates the differ-
ence between the ﬁne-grained EMD data and aggregate imple-
mentation scores—each of the 3 patients has different clinical
behaviors, but irrespective of that, all have the same average
medication coverage over a 3-month time interval.9 Therefore,
CMA scores must be interpreted with caution and initial gran-
ularity maintained by considering shorter time intervals, to avoid
further loss of information.29
Compared with objective reports, patient self-reported imple-
mentation of a dosing regimen is affected by recall bias, which
limits its use in clinical research (see Table I). Several question-
naires are available, most commonly used being the Medication
Adherence Report Scale30 and the Morisky Medication Adherence
Scale.31 Although subject to potential recall bias, the quality of
patient-reported implementation can be improved by intelligent
questionnaire design that, for instance, uses clearly deﬁned terms,
facilitates recall and response, and normalizes nonadherence. In
medical practice, patient (self-) reports of nonadherence are the
most cost-effective method of adherence monitoring available.
Self-report questionnaires can provide valuable information for
research and clinical practice, particularly when linked with EMD,
prescribing, or dispensing data.32
Determinants of implementation. Each person’s will-
ingness and ability to implement therapy as prescribed may be
inﬂuenced by personal characteristics, lifestyle factors, attitudes,
beliefs, skills, and by his or her ability to make a habit out
of medication taking and build it into his or her daily routine.
A wide range of factors—social and economic, health care
team and system-related, disease-related, therapy-related, and
patient-related (see later papers in this issue by van Boven et al,
Braido et al, and Costello et al)—have all been shown to play
a part in the successful implementation of asthma and COPD
medications.33
For example, a recent pharmacy-based asthma study explored
the frequency and drivers of patients’ spontaneously changing
inhaled corticosteroid (ICS) dose. The authors found that 21%
of patients had spontaneously changed the dose over the last 3
months and that patient perception of asthma as a concern in
their life was the characteristic most strongly associated with
changing doses.34 In an Australian study, which used electronic
monitoring to measure adherence to ﬁxed combination therapy
in adults with asthma, barriers to implementation included
concern about, or experience of, side effects while facilitators to
implementation included the belief that asthma is a long-term
condition, the belief that treatment is necessary to keep asthma
under control, being willing to (try) to take treatment every day,
and having a medication-taking routine in place.35
In COPD, a study of implementation and its correlates in
Global Initiative for Chronic Obstructive Lung Disease stages
II-IV, patients were asked to self-report (via questionnaire) their
implementation of respiratory drugs (over the past 3 months)
and their perception of therapy.36 A total of 45% of the
respondents admitted to having forgotten their respiratoryate initiation but good implementation. B, Patient with suboptimal
in timing of drug intakes). C, Patient with excellent implementation
toring devices; EMR, electronic medical records. (Adapted with
monceau J, Ruppar T, et al. A new taxonomy for describing and
-705.9)
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perceived beneﬁt. Risks of accidental omissions were signiﬁcantly
higher in patients who complained about having too many
medications to take on a daily basis and among current smokers.
Women were more likely to interrupt therapy intentionally.
In asthma and COPD, assessment of medication imple-
mentation is also subject to patients’ ability to master (and
maintain mastery of) their prescribed inhaler device(s). Chal-
lenges introduced by inhaled medications can include a combi-
nation of delivery issues (eg, knowing the sequence of steps
required to use the inhaler correctly, successful dose preparation
[eg, insertion of a tablet into an inhaler; inhaler positioning],
inspiratory ﬂow rate, and in pressurized metered-dose inhalers,
dose actuation and coordination with breath inhalation); prac-
tical issues (eg, integration and scheduling with coexisting
medications, storage, and device cleaning); and psychosocial
challenges (eg, self-consciousness about inhaler use in pub-
lic).37,38 These issues are discussed in detail elsewhere in this
issue: Braido et al.39
Implications for research and practice. In summary,
adherence studies need to be thoughtfully designed to target
implementation speciﬁcally, using EMDs as the ﬁrst choice
assessment method where possible or, linked dispensing and
patient reports (as relevant). There remain practical barriers to
the optimum integration of EMDs into current clinical practice,
among them: patient mistrust, complexities and/or burden of
use, device failures, and, importantly, cost. Wider uptake of
available devices may address some of these challenges through
reduction in unit cost, improved usability (facilitated by broader
user feedback), and exposure and/or familiarity to devices (eg,
EMD integration into smartphones) countering any initial
skepticism toward digital innovations. Irrespective of the method
of evaluation chosen, clear justiﬁcation and documentation of
the chosen approach (questionnaire/computation) should be
provided to enable meaningful interpretation and reproducibility
of the results.
Medication persistence and discontinuation
Persistence in observational studies versus
RCTs. The concept of treatment persistence is ostensibly a
research construct, traditionally used in epidemiology (in relation
to cohort studies) and often overlooked in RCTs. It is used to
infer the degree of acceptability and/or patient satisfaction with a
prescribed treatment regimen, that is, the patient’s willingness
and/or ability to implement over a predeﬁned follow-up period;
nonpersistence will be censored if treatment discontinuation is
not observed during the deﬁned period of follow-up.
Although in RCTs early discontinuation is relevant for
estimates of treatment efﬁcacy and satisfaction over relatively
short time periods, observational studies provide complementary
information on time to treatment discontinuation in routine care
over the longer term (within treatment episodes that need careful
deﬁnition).
Measurement of persistence. Treatment discontinuation
can be assessed using EMDs, self-report (by asking patients about
their current use, or time of discontinuation), and dispensing
data (see Table I).
Within the routine care setting, dispensing and/or reﬁll
records are the gold standard for persistence evaluations and havebeen the main source of data for persistence studies to date. Yet
they are not without limitations, particularly in terms of the
granularity—the sampling rate at which it is possible to assess
changes in the dynamic process of implementation and persis-
tence (see Table I). Dispensing and/or reﬁll records are, for
example, unable to differentiate between the moment of
discontinuation and the end of a treatment episode, potentially
deﬁning any gap in treatment as nonpersistence. The concept of a
treatment gap (time between date of last prescription issued in a
given treatment episode and date of the following prescription, if
available) is used to differentiate between implementation and
nonpersistence across chronic disease adherence research, typi-
cally deﬁning nonpersistence as discontinuation of the therapy
class after a prespeciﬁed permitted gap between reﬁlls (eg, 30-,
60-, and 90-day reﬁll gaps, depending on the average prescription
duration).16,40,41 Although this concept has sound clinical
rationale for conditions with consistent symptoms or a progres-
sive disease course (eg, COPD), the common use of self-
management plans and/or as-needed therapy in mild asthma
and episodic use in seasonal disease present real challenges for
asthma adherence research and more accurate methods need to
be developed for assessing discontinuation, ideally using multiple
data sources.
Electronic monitoring devices offer a means of more intensive
objective monitoring of adherence behaviors—identifying the
exact date and/or time of ﬁrst, subsequent, and ﬁnal drug
administrations (see Table I). They are a valuable tool in niche
routine care settings where close adherence monitoring is
required, for example, severe asthma services, and are the gold
standard for monitoring drug exposure and discontinuation
(and comparisons with patient-reported measures).
Determinants of persistence. In routine care, persistence
to maintenance asthma and COPD medication is often poor and
differs between the 2 conditions. An EMR study that evaluated
persistence (ie, time to discontinuation, TTD) across 5 classes of
asthma and COPD therapies (ICS, ICS/long-acting b2-agonists
[LABA], long-acting muscarinic antagonists, and theophylline)
found signiﬁcantly longer TTD for patients with physician-
diagnosed COPD compared with asthma.42 Although patients
with COPD in the study displayed both higher implementation
(deﬁned by MPR) and greater TTD than patients with asthma,
the likelihood of persistence at 1 year was similar for both patient
populations.
In COPD, studies have shown an association between
nonpersistence to tiotropium and a number of factors.43 For
example, a retrospective study of persistence with tiotropium in a
Japanese population with COPD found the following patient
characteristics to be predictors of discontinuation within the ﬁrst
year of drug therapy: young age, current smoking status, less
severe disease, and absence of respiratory symptom alleviation.44
Some of these associations bore out in a similarly designed
French EMR study. Of the 1147 newly treated patients, 64%
persisted with tiotropium over a 12-month period. Discontinu-
ation rates were lower in patients with more severe disease, when
at least two other respiratory drugs were co-prescribed and/or if
treatment was initiated by a private sector specialist or hospital
physician. Age and gender did not appear to have any clear effect
on discontinuation rates.45
Other treatment-level determinants can also play a role in
early discontinuation. A negative association has been shown
TABLE II. Recommendations for asthma and COPD medication adherence research and clinical assessment in the context of the ABC
conceptualization of adherence steps
Topic Initiation Implementation Discontinuation
Prevalence  Quantify the extent of medication
noninitiation in everyday routine care,
across a range of health care systems/
settings
 Quantify the prevalence and charac-
terize the nature of implementation
behaviors by targeted evaluations
(separate to initiation and persistence
assessments) and in both experimental
(via RCTs) and real-life (via
observational studies) settings
 Quantify medication persistence rates
over a range of:
B Time periods
B Disease states
B Health care systems/settings
Measurement  Integrate EMRs (eg, prescribing and
dispensing records  EMD data) to
provide a more complete picture of
medication initiation, both initiation
occurrence and time to initiation
 Reﬁne of initiation patient reports: use
of appropriate wording and question
timing to capture accurate patient data
 Use EMD data to assess implementa-
tion where study settings and resources
permit
 Document and justify the choice of
measurement tools to enable
meaningful interpretation and
reproducibility
 For working with dispensing data:
develop (and apply) standardized
methodologies to:
B Differentiate accurately between
implementation and persistence
behaviors
B Retain maximum data granularity
and clinical meaning
 Optimize reliability of implementation
self-reports by careful question design
(ie, improve report accuracy) and
linkage with other data sources
 Use EMD data and/or linked data
sources to improve the accuracy of
nonpersistence assessments
 For working with dispensing data:
B Develop (and apply) standardized
methodologies to differentiate
accurately between implementation
and persistence behaviors (draw on
real-world seasonal and self-
management prescribing and dose
adjustment patterns)
B Deﬁne appropriate treatment gaps
for different clinical scenarios
(eg, for different: levels of disease
severity and symptom proﬁles—
variable vs persistent)
Determinants  Explore risk factors for noninitiation
(eg, sociodemographics, disease stage)
 Identify modiﬁable determinants of
noninitiation (eg, beliefs about illness
and treatment, stigma perceptions)
 Improve agreement implementation
determinant deﬁnitions
 Develop standardized model method-
ologies for evaluating implementation
determinants
 Characterize determinants of non-
persistence to:
B Enable early identiﬁcation
B Target interventions
Consequences  Evaluate the speciﬁc effects of non- or
delayed medication initiation on clin-
ical outcomes
 Explore the time-varying nature of
implementation on health outcomes
(eg, via longitudinal study designs)
 Evaluate the time sequence of adher-
ence behaviors and outcomes to
determine causality
Interventions  In clinical practice: improve timely
assessment of medication initiation
(and/or barriers to) to inform
interventions
 Identify target patient groups for EMD
use
 Explore moderators of implementation
intervention effectiveness
 In clinical practice: combine clinician-
delivered patient support with EMDs
(as appropriate and available) to
improve implementation
 In clinical practice: enquire speciﬁcally
about treatment discontinuation
(and its causes) in an empathic manner
to inform targeting of interventions
and support treatment reinitiation
ABC, Ascertaining barriers to compliance; COPD, chronic obstructive pulmonary disease; EMD, electronic monitoring devices; EMR, electronic medical records; RCT,
randomized controlled trial.
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ications) and persistence—patients with COPD prescribed
multiple (2) long-acting inhaled therapies have been shown
to have a 40% higher treatment discontinuation rate than
patients taking a single long-acting inhaled drug.46 Differential
12-month persistence rates have also been demonstrated to
different COPD therapies, with tiotropium monotherapy
associated with higher persistence rates than guideline-
recommended alternatives.45,47
In asthma, a dispensing records study of persistence to ﬁxed
dose combination (FDC) maintenance therapy found that, on
average, more than half the patients (n ¼ 5504) ﬁlled a 30-day
prescription only once over the 1-year interval. Higher persis-
tence was associated with being male, being older than 35 years,having a comorbid disorder, having a lower monetary value
copay ($1.01 vs $10), previous bronchodilator use, and a pre-
scription for higher dose maintenance therapy. The authors
concluded that most adult patients with asthma taking FDC
controller therapy obtained a single ﬁll before abandoning their
controller medication and called for a reappraisal of current
treatment guidelines and educational strategies for both providers
and patients.48 However, appropriate prescribing must be
determined to enable correct measurement of persistence rates.49
Other controller therapy persistence studies involving adult
patients with asthma have reported persistence rates of 15%
at 12 months in patients prescribed ﬁxed dose combination
ICS/LABA and10% in those on ICS/LABA as separate inhalers,
or ICS alone.50,51 Persistence rates in the 2 studies appeared to be
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treatment-related factors (eg, daily dosing frequency).
Implications for research and practice. Although
somewhat conceptual and arbitrarily modiﬁable by the duration
of the deﬁned outcome period, the concept of treatment
discontinuation does hold clinical value.
Interpretation of persistence requires the development of a
consensus deﬁnition of a clinically meaningful treatment gap
(particularly in variable conditions such as asthma) to help
differentiate between treatment holidays, ﬂexibility of dosing
regimen, and true nonpersistence.
In clinical practice, if a clinician suspects, or if a patient
reports, no recent medication use, it is important to understand
whether it is a case of true discontinuation or possible suboptimal
implementation and then to investigate and address possible
causes of discontinuation. Use of nonjudgmental and empathic
language and/or tone is recommended to encourage patients to
disclose their adherence decisions. The assessment of persistence
is critical to interpreting the patient’s clinical scenario and
medication needs and key to preventing unnecessary escalation of
therapy and associated health care costs (as discussed further by
van Boven et al in their paper in this issue).52
CONCLUSIONS
The ABC taxonomy proposes that the ultimate goal of
adherence management is “to achieve and maintain the best
use, by patients, of appropriately prescribed medicines in order
to maximize beneﬁt and minimize the risk of harm.”9 Devel-
opment of the taxonomy has been an important step toward
efﬁcient medication adherence research. Subdividing the hith-
erto single act of medication adherence into discrete concepts of
(A) initiation, (B) implementation, and (C) persistence helps to
focus research questions and identify measures and corre-
sponding data sources to answer them. Better characterization
and consideration of the determinants of associated behaviors
will help guide clinical use of available adherence interventions
to maximize potential beneﬁt, minimize potential risk, and
avoid unnecessary treatment escalation (see the paper by Dima
et al in this issue).53
The ABC taxonomy has broad relevance across all medical
conditions, and its adoption is critical to improving clinical
understanding of patients’ adherence behaviors and to setting
new standards for adherence research. However, it must be
interpreted and applied in the context of the speciﬁc character-
istics of the condition under consideration. In asthma and
COPD, the inhaled route of therapy delivery is central, in
particular, for its potential capacity to affect all steps of the
adherence pathway negatively. Furthermore, the cyclic and often
seasonal nature of respiratory symptoms seen in asthma often
complicates medication adherence due to ﬂexible dosage rec-
ommendations in self-management plans.
From an evidence synthesis and research efﬁciency perspec-
tive, future success of the ABC taxonomy within asthma and
COPD requires investigators to address unmet research needs
(see Table II) through consistent use (and clear documentation
of use) of the proposed terminology and recognized evaluation
measures. All measures have limitations (see Table I for a
comparative overview of their characteristics). Dispensing data
are unable to capture more granular ﬂuctuations in adherence
behaviors. The accuracy of self-reports varies substantiallydepending on questionnaire design decisions that can limit or
improve the respondent’s ability to accurately remember and
report on their behaviour.54,55 The use of EMD data is not
only limited by a number of practical issues (eg, device failure,
complexity, mistrust of technologies, expense), but also by the
availability of only relatively small-scale, short-term data
collection due to practical constraints. Where feasible, linkage
of multiple data sources enables richer explorations of patient
behaviors, validation of existing measures, and improved clinical
interpretation. Therefore, generating robust research evidence
requires thoughtful selection of the best assessment approaches
available for the speciﬁc aspect of adherence and particular
research question under consideration and clear reporting of the
research question(s), assessment method(s), results and speciﬁc
implications, and relevant context. Within the clinical setting,
reviewing a combination of reﬁll history, self-report, and EMD
data can help the health care professional understand the
contribution of adherence behaviors to the patient’s health
status. Access to such data provides a starting point for dis-
cussing potential barriers to medication use, and by selecting
the optimum measurement-guided management approach,
through a process of shared-decision making,56 patient
empowerment is appropriately placed at the heart of good
clinical care.REFERENCES
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